GWM
SRPT icon

Geneos Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Geneos Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-53
Closed -$8.49K – 3222
2025
Q1 		$8.49K Buy
53
+37
+231% +$3.9K ﹤0.01% 2614
2024
Q4 		$1.95K Buy
+16
New +$1.96K ﹤0.01% 2603
2024
Q2 		– Sell
-4
Closed -$518 – 2170
2024
Q1 		$518 Buy
+4
New +$490 ﹤0.01% 2120
2022
Q3 		– Sell
-118
Closed -$8K – 2522
2022
Q2 		$8K Hold
118
– – ﹤0.01% 2049
2022
Q1 		$9K Hold
118
– – ﹤0.01% 2134
2021
Q4 		$10K Hold
118
– – ﹤0.01% 2191
2021
Q3 		$11K Hold
118
– – ﹤0.01% 2194
2021
Q2 		$8K Hold
118
– – ﹤0.01% 2305
2021
Q1 		$8K Hold
118
– – ﹤0.01% 2499
2020
Q4 		$8K Hold
118
– – ﹤0.01% 2327
2020
Q3 		$16K Buy
118
+50
+74% +$7.6K ﹤0.01% 1767
2020
Q2 		$11K Sell
68
-50
-42% -$6.8K ﹤0.01% 1892
2020
Q1 		$11K Hold
118
– – ﹤0.01% 1787
2019
Q4 		$15K Hold
118
– – ﹤0.01% 1815
2019
Q3 		$8K Hold
118
– – ﹤0.01% 1978
2019
Q2 		$17K Hold
118
– – ﹤0.01% 1720
2019
Q1 		$14K Sell
118
-100
-46% -$12.9K ﹤0.01% 1724
2018
Q4 		$23K Hold
218
– – ﹤0.01% 1446
2018
Q3 		$35K Sell
218
-180
-45% -$24.6K ﹤0.01% 1339
2018
Q2 		$52K Sell
398
-120
-23% -$11.3K ﹤0.01% 1025
2018
Q1 		$38K Buy
518
+400
+339% +$26.7K ﹤0.01% 1129
2017
Q4 		$6K Hold
118
– – ﹤0.01% 1782
2017
Q3 		$5K Hold
118
– – ﹤0.01% 1770
2017
Q2 		$3K Sell
118
-333
-74% -$10.8K ﹤0.01% 1868
2017
Q1 		$13K Buy
451
+250
+124% +$7.74K ﹤0.01% 1400
2016
Q4 		$5K Sell
201
-50
-20% -$2.01K ﹤0.01% 1645
2016
Q3 		$15K Sell
251
-50
-17% -$1.51K ﹤0.01% 1242
2016
Q2 		$6K Buy
301
+100
+50% +$1.85K ﹤0.01% 1479
2016
Q1 		$4K Buy
+201
New +$3.51K ﹤0.01% 1564

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Geneos Wealth Management's SRPT Position: Q2 2025 in Review

Geneos Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 53 shares — an estimated $8.49K sold.

Geneos Wealth Management first reported a position in SRPT in Q1 2016 and held it in 29 quarters. The position peaked at $52K in Q2 2018. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Geneos Wealth Management reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 53 Sarepta Therapeutics shares in Q2 2025, an estimated $8.49K.
  • Geneos Wealth Management first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 29 quarters.
  • Geneos Wealth Management's Sarepta Therapeutics position peaked at $52K in Q2 2018.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Geneos Wealth Management's 13F filing for Q2 2025, filed 18 Aug 2025.